DOW JONES27,081.36-879.44 -3.15%
S&P 5003,128.21-97.68 -3.03%
NASDAQ8,965.61-255.67 -2.77%

H.C. Wainwright Reiterates Buy on Y-mAbs Therapeutics, Raises Price Target to $41

H.C. Wainwright reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and raises the price target from $40 to $41.

Benzinga · 01/28/2020 12:27

H.C. Wainwright reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and raises the price target from $40 to $41.